NCT03469336View on ClinicalTrials.gov

Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

March 20, 2019

Study Completion Date

March 20, 2019

Conditions
Psoriasis
Interventions
DRUG

PF-06763809

Three different concentrations will be administered to three different treatment fields: 2.3%, 0.8% and 0.23%

OTHER

Vehicle

Vehicle matching PF-06763809.

DRUG

Calcipotriene/calcipotriol

Calcipotriene/calcipotriol 50 ug/mL solution

DRUG

Betamethasone

Betamethasone 1 mg/g solution

Trial Locations (2)

10783

Rothaar Studien GmbH, Berlin

20095

bioskin GmbH, Hamburg

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03469336 - Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter